TickerTalks
Browse all tickers →
TickerTalks›$CYTK
CYCYTK

Cytokinetics, Incorporated

$CYTK·$7.8B·Biotechnology·Healthcare
$63.92+0.8%YTD+1.2%1Y+1.8%
Price updated 6h ago·X counts updated 4d ago
CYCYTK
$CYTKCytokinetics, Incorporated
$63.92+0.77%143 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CYTK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

143X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CYTK's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 61% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-15

Cytokinetics catches a bid as NVS loses pipeline elsewhere, positioning it and MLYS as clear cardio M&A candidates. Posters speculate Novartis could re-approach for both oHCM and nHCM indications now that CYTK is in the driver's seat.

Read what X is saying about $CYTK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CYTK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Cytokinetics is a cardio M&A target — the X thread sees Novartis re-approaching now that CYTK is in the driver's seat.

Cytokinetics is a late-stage cardio biotech — aficamten in obstructive and non-obstructive hypertrophic cardiomyopathy, with Camzyos (Novartis) as the direct comp. The M&A speculation has resurfaced after Novartis's pipeline loss elsewhere.

  • The business is pre-commercial on aficamten: Q1 revenue inflecting from a tiny base (+1,126% YoY) at a -6% operating margin — the P&L is dominated by trial costs, and standard multiples don't apply because the stock trades on readout and deal-math optionality.
  • The strategic positioning is specific: with Novartis losing pipeline elsewhere, Cytokinetics and MLYS become clear cardio M&A candidates — a Novartis re-approach for both oHCM and nHCM would reset the valuation materially.
  • 52-week range position is 35% with volume at 87% of average — the chart has digested earlier excitement and is coiled around a potential takeout premium, with the Nov 4 earnings as the near-term operational anchor.

Nov 4 Q3 is the gate — any aficamten commercial-launch cadence update plus a Novartis-strategic-conversation hint extends the move. A disappointing launch slope or no M&A development and the stock stays range-bound ahead of the next data event.

Agrees with X sentimentThe thread's M&A framing is substantively right — Novartis's pipeline situation plus Cytokinetics' aficamten positioning make a re-approach plausible, and CYTK + MLYS as the pure cardio-takeout pair is the natural pairing the sell-side has flagged.

What to watch: Nov 4 Q3 — aficamten launch metrics, Novartis strategic commentary, operating cash runway, and any oHCM / nHCM label commentary. A disappointing launch slope or dilutive raise is the clear invalidator.

On the calendar: 2026-11-04 — Q3 earnings

Read the AI verdict on $CYTK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Late-stage biotech with cardiac muscle modulators targeting hypertrophic cardiomyopathy and heart failure.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CYTK.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $CYTK

Neutral — Late-stage biotech with cardiac muscle modulators targeting hypertrophic cardiomyopathy and heart failure.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-56.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
84.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
140%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
90.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-1.50$-1.63+8.0%
Q1 2026May 5, 2026$-1.67$-1.670.0%
Q4 2025Feb 24, 2026$-1.50$-1.48-1.4%
Q3 2025Nov 5, 2025$-2.55$-1.59-60.4%
Next earningsWed, Nov 4·consensus EPS $-1.45

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$19.4M+1125.8%87.6%-949%$-1.67$-151.4M
Q4 FY25$17.8M+4.9%83.9%-1005%$-1.49$-148.3M
Q3 FY25$1.9M+318.1%-38.4%-8613%$-2.55$-116.9M
Q2 FY25$66.8M+26714.9%96.6%-167%$-1.12$-132.4M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$150.6M$133.9M – $217.8M-$6.05-$6.45 – -$4.1116
FY27$424.5M$324.1M – $573.7M-$4.47-$5.37 – -$3.0316
FY28$891.6M$701.8M – $1.2B-$2.11-$4.06 – -$0.2216
FY29$1.5B$1.2B – $2.1B$0.65$0.46 – $0.9614
FY30$2.3B$1.8B – $3.1B$3.85$2.69 – $5.7014

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.365-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 12Robert I BlumCEO7.5K sh$472KSellOct 6Malik Fady IbrahamEVP Research & Development3.5K sh$215KSellSep 28Robert I BlumCEO7.5K sh$491KSellSep 22Malik Fady IbrahamEVP Research & Development3.5K sh$239KSellSep 15Robert E LandryDirector1.0K sh$72KSellSep 15Robert I BlumCEO97.9K sh$6.8MSellSep 14Robert I BlumCEO7.5K sh$551KSellSep 11Robert E LandryDirector1.0K sh$75KSellSep 8Malik Fady IbrahamEVP Research & Development3.5K sh$264KSellSep 1Parshall B LynneDirector5.0K sh$357K
1–10 of 42
+ 46 other (30 exempts · 15 awards · 1 gift) in window

See when $CYTK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 278-K — Item 5.07: Shareholder vote
AI summary

Cytokinetics, Incorporated held its Annual Meeting of Stockholders on May 27, 2026, with 116,125,730 of 124,237,822 eligible shares (93.47%) represented. Stockholders voted on proposals as described in the proxy statement; final vote tallies are reported. Routine annual meeting governance disclosure for the cardiovascular drug developer.

424B5Prospectus supplement (offering)May 7424B5
AI summary

Cytokinetics (CYTK) filed a 424B5 prospectus supplement for the sale of 9,859,155 shares of common stock at $71.00 per share, with underwriters purchasing at the same price (no underwriting discount specified in excerpt). Total gross proceeds are approximately $700 million. This is an equity dilution event of material size for the clinical-stage cardiovascular biopharmaceutical company, which is advancing aficamten for obstructive hypertrophic cardiomyopathy.

424B5Prospectus supplement (offering)May 5424B5
AI summary

Cytokinetics (CYTK) filed an earlier 424B5 prospectus supplement for a $650 million equity offering; the price per share was not specified in the available excerpt. This appears to be a preliminary prospectus supplement prior to the final pricing at $71.00 per share announced in the subsequent 424B5. The offering reflects Cytokinetics' capital needs to fund late-stage clinical programs including aficamten.

+ 13 other (4 routine 8-Ks · 4 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)defenseworld.net·2d agoHead to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)defenseworld.net·3d agoCytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026globenewswire.com·4d agoAnalyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)defenseworld.net·8d agoCytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026globenewswire.com·14d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport